Ayala Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Dec '23 Dec 31, 2023	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-48.07	-48.07	-38.01
Depreciation & Amortization	0.37	0.37	0.16
Asset Writedown & Restructuring Costs	0.15	0.15	-
Stock-Based Compensation	1.22	1.22	2.24
Other Operating Activities	15.72	15.72	-
Change in Accounts Receivable	0.23	0.23	-0.23
Change in Accounts Payable	-0.72	-0.72	-0.47
Change in Income Taxes	0.45	0.45	0.47
Change in Other Net Operating Assets	1.17	1.17	1.34
Operating Cash Flow	-29.49	-29.49	-34.51
Sale of Property, Plant & Equipment	4	4	-
Cash Acquisitions	1.91	1.91	-
Other Investing Activities	0.04	0.04	-0
Investing Cash Flow	5.95	5.95	-0
Short-Term Debt Issued	6	6	-
Total Debt Issued	6	6	-
Net Debt Issued (Repaid)	6	6	-
Issuance of Common Stock	20	20	0.51
Other Financing Activities	-	-	-0.62
Financing Cash Flow	26	26	-0.1
Foreign Exchange Rate Adjustments	0.03	0.03	-
Net Cash Flow	2.49	2.49	-34.62
Free Cash Flow	-29.49	-29.49	-34.51
Free Cash Flow Margin	-226807.69%	-226807.69%	-4986.99%
Free Cash Flow Per Share	-4.90	-4.90	-11.92
Cash Income Tax Paid	0.37	0.37	0.24
Levered Free Cash Flow	-3.25	-3.25	-
Unlevered Free Cash Flow	-3.25	-3.25	-
Change in Net Working Capital	-17.2	-17.2	-

Source: S&P Capital IQ. Standard template. Financial Sources.